GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Monivent AB (XSAT:MONI) » Definitions » ROCE %

Monivent AB (XSAT:MONI) ROCE % : -98.65% (As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Monivent AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Monivent AB's annualized ROCE % for the quarter that ended in Sep. 2023 was -98.65%.


Monivent AB ROCE % Historical Data

The historical data trend for Monivent AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Monivent AB ROCE % Chart

Monivent AB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROCE %
Get a 7-Day Free Trial -64.01 -99.40 -46.19 -50.25 -70.70

Monivent AB Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -109.24 -107.13 -98.08 -92.21 -98.65

Monivent AB ROCE % Calculation

Monivent AB's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=-14.324/( ( (22.925 - 1.596) + (21.294 - 2.102) )/ 2 )
=-14.324/( (21.329+19.192)/ 2 )
=-14.324/20.2605
=-70.70 %

Monivent AB's ROCE % of for the quarter that ended in Sep. 2023 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Sep. 2023 )  (Q: Jun. 2023 )(Q: Sep. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Sep. 2023 )  (Q: Jun. 2023 )(Q: Sep. 2023 )
=-11.972/( ( (16.406 - 2.641) + (14.276 - 3.77) )/ 2 )
=-11.972/( ( 13.765 + 10.506 )/ 2 )
=-11.972/12.1355
=-98.65 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Monivent AB  (XSAT:MONI) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


Monivent AB ROCE % Related Terms

Thank you for viewing the detailed overview of Monivent AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Monivent AB (XSAT:MONI) Business Description

Traded in Other Exchanges
N/A
Address
Regnbagsgatan 8B, Gothenburg, SWE, SE-417 55
Monivent AB is a medtech company focused on improving the care given to newborn babies in need of respiratory support at birth. The company has developed a patented solution that provides continuous feedback on the volumes of air given to the newborn during manual ventilation. The airflow is measured directly in the face mask and feedback on the ventilation parameters is displayed numerically and graphically in real-time on the external monitor. The company's product is Monivent Neo100.